These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18627334)

  • 1. Docetaxel in the management of prostate cancer: current standard of care and future directions.
    De Dosso S; Berthold DR
    Expert Opin Pharmacother; 2008 Aug; 9(11):1969-79. PubMed ID: 18627334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
    Logothetis CJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel-based combination therapy for castration-resistant prostate cancer.
    Galsky MD; Vogelzang NJ
    Ann Oncol; 2010 Nov; 21(11):2135-2144. PubMed ID: 20351071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of chemotherapy in prostate cancer.
    Nader R; El Amm J; Aragon-Ching JB
    Asian J Androl; 2018; 20(3):221-229. PubMed ID: 29063869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should docetaxel be administered earlier in prostate cancer therapy?
    Graff JN; Beer TM
    Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic chemotherapy for prostate cancer: Who and when?
    Moss RA; Petrylak DP
    Curr Treat Options Oncol; 2006 Sep; 7(5):370-7. PubMed ID: 16904054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
    Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.